We’ve rebranded some of our products, learn more ›
CODEX® is now PhenoCycler, Phenoptics™ is now Phenolmager.
The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients
December 13, 2022
Endometrial cancer is the most common gynecologic malignancy diagnosed in western countries, with most cases diagnosed as low-grade, early-stage disease. Although most patients get cured with current treatment strategies, a subset of patients develop recurrent disease.
Currently, prediction tools rely on clinical, pathologic, and molecular characteristics and their performance is far from ideal. Therefore, new prognostic biomarkers are needed to improve patient risk classification.
In this webinar we will discuss the use of the PhenoImager HT (AKOYA Biosciences) platform to dissect the immune microenvironment of low-grade early-stage endometrial carcinomas. We will present advances in the use of immune microenvironment data to improve relapse risk prediction.
Attend this webinar to:
- Illustrate the heterogeneous tumor immune microenvironment of low-grade early-stage endometrial tumors
- Describe how different immune microenvironments differ in terms of cell phenotypes and spatial interaction
- Demonstrate how immune microenvironment information can improve patient risk stratification
Video
Speaker
Álvaro López-Janeiro MD
Clínica Universidad de Navarra (Pamplona, Spain)
Biography
Álvaro López-Janeiro earned his medical degree from the University of Navarra and completed his residency at University Hospital La Paz (Madrid, Spain). As a pathologist and scientist, Álvaro helps to develop platforms to study molecular biomarkers for prediction of response or resistance to immunotherapy and mechanisms of immune evasion. He was involved in a pivotal study that showed neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Currently, his main focus the study of low-grade early-stage endometrial cancer patients -developing new biomarkers to predict relapse of endometrial cancer.
